IRX 211 OPIOID ALTERNATIVE, page-2

Great post @sapporo. I too noticed the change in wording. The AGM presentation stated pain and two weeks later the wording has changed including a new potential ethics approval target and even larger medical area to target. In 2023 the options as you stated for pain relief in our target market above are pretty grim. All are highly addictive and really not great to use more than short term. Again another tick for our great leadership team as our potential twin turbo remedies could be a game changer in this area of patient treatment!!!!

Still the elephant in the room is funding..we would be getting close to 1 million in the bank. After some great announcements we are still stuck under .5. Hope Darryl has a good plan!!!!